Wplyw preparatow TFX-Polfa i lewamizolu na reaktywnosc immunologiczna swin w przebiegu amyloidogenezy

• Autorzy: Rotkiewicz Z
• Języki publikacji: PL

Abstrakty

PL

W przebiegu doświadczalnej amyloidozy u świń, wywołanej domięśniowym podawaniem kazeinianu sodu, określono wpływ lewamizolu i preparatu „TFX-Polfa" na reaktywność układu immunologicznego w zakresie nieswoistej i swoistej odporności komórkowej i humoralnej. Tę ostatnią indukowano żywą szczepionką wirusa chA. Z przeprowadzonych badań wynika, że w okresie przedamyloidowym następuje wzrost, a w fazie amyloidowej spadek wartości wszystkich badanych parametrów, tj. liczby limfocytów T i B, ich aktywności metabolicznej, aktywności fagocytarnej leukocytów, poziomu dopełniacza, lizozymu i przeciwciał seroneutralizujących wirus chA. Immunorekonstrukcyjny wpływ badanych immunostymulatorów był większy w drugiej fazie - amyloidowej i przejawiał się zmniejszeniem odkładania złogów amyloidu w narządach, co oznacza, że wymierna skuteczność preparatu „TFX-Polfa" była wyższa niż lewamizolu.

EN

The effect of levamisole and „TFX-Polfa" preparation on the immunological system reactivity concerning cellular and humoral immunity, specific and non-specific, was deter­mined in the course of experimental amyloidosis induced by means of sodium caseinate injected intramuscularly. The humoral immunity was induced using attenuated ADV vaccine. The research results show that the values of all examined parameters, ie the number of T and В lymophocytes, their metabolic activity, phagocytic activity of leucocytes, the levels of complement, lysozyme and seroneutralising antibodies for ADV increased at the stage of pre-amyloidosis and decreased at that of amyloidosis. The immunoreconstructive effect of examined immunostimulators was bigger in the phase of amyloidosis and was revealed by decrease in deposit accumulation in the organs; the efficiency of „TFX-Polfa" preparation was higher than that of levamisole.

Słowa kluczowe

PL

choroby zwierzat; trzoda chlewna; uklad odpornosciowy; odpornosc humoralna; odpornosc komorkowa; immunostymulatory; reaktywnosc; preparat TFX; lewamizol; amyloidoza; amyloidogeneza

EN

animal disease; pig; immune system; humoral immunity; cellular immunity; immunostimulant; reactivity; TFX-Polfa preparation; levamisole; amyloidosis; amyloidogenesis

• Wydawca: -
• Czasopismo: Acta Academiae Agriculturae ac Technicae Olstenensis. Veterinaria
• Rocznik: 1995
• Tom: 22,Suppl.B
• Strony: 1-59
• Opis fizyczny: s.1-59,fot.,rys.,tab.,bibliogr.

Twórcy

autor

Rotkiewicz Z

• Akademia Rolniczo-Techniczna, Olsztyn

Bibliografia

• Adachi N., Koh C. S, Tsukada N., Shoji S., Yanagisawa N. 1988. In vitro degradation of amyloid material by four proteases in tissue of a patient with familial amyloidotic polyneuropa­thy. J. Neurol. Sci., 84(2-3): 295-299.
• Alizadeh Khiavi K., Normand J., Chronopoulos S., Ali A., Ali-Khan Z. 1991. Alzheimer's disease brain derived ubiquitin has amyloid enhancing factor activity: behavior of ubiquitin during accelerated amyloidogenesis. Acta Neuropathol. Berl. 81(3): 280-286.
• Alizadeh Khiavi K., Normand J., Alizadeh Khiavi K, Robitaille Y., Chronopoulos S. 1992a. Ubiquitin profile and amyloid enhancing factor activity in Alzheimer and „normal" human brain extracts. Neurosci. Lett. 139(1): 24-28.
• Alizadeh Khiavi K., Normand J., Chronopoulos S., Ali A., Ali-Khan Z. 1992b. Amyloid enhancing factor activity is associated with ubiquitin. Virchows Arch. A (Path. Anat.) 420: 139-148.
• Alizadeh Khiavi K., Chronopoulos S., Ali-Khan Z. 1994. Ubiquitin profile in inflammatory leu­cocytes and binding of ubiquitin to murine АA amyloid: immunocytochemical and immunogold electron microscopic studies. J. Path. 172(2): 209-217.
• Axelrad M. A., Kisilevsky R., Willmer J., Chen S.J., Skinner M. 1992. Further characterization of amyloid enhancing factor. Lab. Invest. 47(2): 139-146.
• Ballou S. P., Lozański G. 1992. Induction of Inflammatory Cytokine Release from Cultured Human Monocytes by C-Reactive Protein. Cytokine, 4(5):361-368.
• Baltz M. L., Caspi D., Glattaar В. E., Moser U., Pepys M. B. 1984. The failure of ascorbic acid therapy to alter the inductin or remission of murine amyloidosis. Clin. exp. Immun. 57(3): 657-662.
• Bendtzen K. 1988. Interleukin 1, Interleukin 6 and tumor necrosis factor in infection, in­flammation and immunity. Immunology Lett., 19: 183-192.
• Boyum A. 1968. Separation of leucocytes from blood and bone marrow. Scand. J. clin. lab. Invest., 21: 9-17.
• Brandwein S. R., Sipe J. D., Skinner M., Cohen A. S. 1985a. Effect of colchicine on experimental amyloidosis in two СBА/J mouse models. Chronic inflammatory stimulation and administration of amyloid enhancing factor during acute inflammation. Lab. Invest. 52(3): 319-325.
• Brandwein S. R., Sipe J. D, Skinner M., Cohen A. S. 1985b. Prostaglandin E1 inhibition of experimental amyloidosis in CBA/J mice. J.Rheumatol. 12(3):418-426.
• Buckle A. M., Hogg N. 1989. The effect of INFg and colony stimulating factors on the expression of neutrophil cell membrane receptors. J. Immun., 143: 2295-2305.
• Canning P. C., Neill J. D. 1989. Isolation and characterization of interleukin-1 from bovine polymorphonuclear leukocytes. J. Leukoc. Biol., 45: 21-42.
• Cathcard E. S., Mullarkey M., Cohen A. S. 1971. Cellular immunity in casein-induced amyloi­dosis. Immunology, 20(6): 1001-1008.
• Chronopoulos S., Lembo P., Alizadeh-Khiavi K., Ali-Khan Z. 1992. Ubiquitin: Its Potential Signi­ficance in Murine AA Amyloidogenesis. J. Path., 167: 249-259.
• Cockerell G. L., Baldwin C. L. 1979. Increased spontaneous erythrocyte rosette formation of feline lymphocytes preincubated at 37°C. J.Immun.Meth., 28:369-379.
• Cohen A. S., Calkins E., Mullinax P. F. 1962. Studies in Experimental Amyloidosis. III. The Effect of Cortisone Administration on the Incidence of Casein-Induced Amyloidosis in the Rabbit. Arch. Intern. Med., 110(5): 569-573.
• Cohen A. S., Shirahama T. 1972. Animal model for human disease: spontaneous and induced amyloidosis. Am. J. Path., 68(2): 441-444.
• Cohen A. S., Connors L. H. 1987. The pathogenesis and biochemistry of amyloidosis. J. Path., 141: 1-5.
• Dąbrowski M. P., Dąbrowska-Bernstein В. K. 1987. Podstawy immunorekonstrukcyjnej koncep­cji terapeutycznej uwzględniającej zastosowanie preparatu TFX. Terapia i Leki. XV/ XXXVII (4-5): 85-94.
• Dębowy J., Obmińska-Domaradzka B. 1987. Wykorzystanie immunostymulujących właściwości lewamizolu w praktyce weterynaryjnej. Medycyna Wet., 43(6): 357-359.
• Dębowy J., Świtała M. 1987. Lewamizol i nitrogranulogen w immunoprofilaktyce i terapii weterynaryjnej. Nowości Weterynarii, XVII(4): 208-211.
• Duncan I. A., Binns R. M., Duffus P. H. 1989. The null T cell in pig blood is not an NK cell. Immunology, 68(3): 392-395.
• Eganjan T. A., Kuznecova O. P. 1977. Sostojanie gumoral'nogo i kletočnogo immuniteta pri eksperimental'nom amiloidoze. Arch. Pat., 39(4): 44-49.
• Emmrich F., Felber F. 1980. Leukozytenmigrationstest under Agarose (LMTA) Immunologi­sche Arbeitsmethoden. Red. Friemel M. VEB. Gustav Fischer Verlag Jena.
• Felsburg P. J., Edelman R., Gilman R. H. 1976. The „active" E-rosette test correlation with delayed cutaneous hypersensitivity. J. Immun., 116: 1110-1114.
• Felsburg P. J., Edelman R. 1978. The active E-rosette test a sensitive in vitro correlate for human delayed hypersensitivity. J. Immun., 118:62-66.
• Ferszt Т., Endrész V., Seprényi G., Béládi I. 1993. The effect of thymus factor X (TFX-Polfa) on the NK activity of human lymphocytes in vitro. Immunol. Polska, XVIII: 151-157.
• Fitzgerald J., West K., Sonis S., Wilson R. 1983. Polymorphonuclear leukocyte regulation lymphocyte proliferation and differentiation. Immunobiol. 165: 421-436.
• Fizjologiczne podstawy immunoterapii grasiczopochodnym lekiem TFX. 1987. Red. Dąbrow­ski M. P. Przedsiębiorstwo Wydawnictw i Wystaw Przemyślu Chemicznego i Lekkiego „CHEMIL", Warszawa.
• Florey M. J., Peetom F. 1976. Modified E-rosette test for detection of total and active rosette frming lymphocytes. J. Immun. Meth., 13: 201-206.
• Franklin Е. C. 1980. Immunopathology of the amyloid diseases. Hosp. Pract., 15(9): 70-77.
• van Furth R., van Zwet T. L., Leijk P. C. J. 1979. In vitro determination and phagocytosis and intracellular killing by polymorphonuclear and mononuclear phagocytes. Ed. Weir D. M., Handbook of Experimental Immunology. Blackwell Sci.Publ.Oxford London, 32: 1.
• Gajdusek D. C., Beyreuther K., Brown P., Cork L. C., Cunningham D. D., Frangione В., Gibbs C. J. Jr., Goldfarb L. G., Goldgaber D., Hsiao K. K., Koo E. H., Martin L. J., Masters C. L., Odenwald W. F., Price D. L., Prusiner S. В., Ruddle F. H., Safar J., Scangos G., Schmechel D. E. Shashikant C. S., Shichta P. J., Sisodia S. S., Trapp B. D., Unterbeck A., Nostrand W. E. Van, Violette S. M., Walker L. C., Wirak D. 1991. Regulation and genetic control of brain amyloid. Brain Res. Rev., 16: 83-114.
• Galante D., Andreana A, Perna P., Utili R., Ruggiero G. 1982. Decreased phagocytic and bacteri­cidal activity of the hepatic reticuloendothelial system during chronic ethanol treat ment and its restoration by levamisole. J. Reticuloendothel. Soc., 32(3): 179-187.
• Gejyo F., Yamada Т., Odani S., Nakagawa P., Arakawa M., Kunimoto Т., Kataoka H., Susuki M, Hirasawa Y., Shirahama Т., Cohen A. S., Schmid K. 1985. A new form of amyloid protein associated with chronic hemodialysis was identified as b2-microglobulin. Biochem. Biophys. Res. Commun. 129: 701-706.
• Giełdanowski J. 1981. Immunomodulators-Thymus Factor X (TFX) and Levamisole in Imunе Reactions and Inflammatory Processes. Arch. Immun. Ther., 29: 121-132.
• Giełdanowski J. 1980. Immunoregulatory odpowiedzi immunologicznej. Immunol. Polska V(4): 347-359.
• Giełdanowski J. 1983a. Immunomodulatory drugs as the stimulatores of proliferative process. Arch. Immun. Ther., 31: 345-348.
• Giełdanowski J. 1983b. Influence of Histamine-Like Drugs and Immunomodulators on the Spontaneous E Rosette Formation. Arch. Immun. Ther., 31: 353-355.
• Giełdanowski J., Ślopek S., Kowalczyk-Bronisz S. 1980. Immunobiological and Pharmacological Properties of Thymus Factor X (TFX). II. Immunotropic activity. Arch. Immun. Ther., 28: 853-857.
• Giełdanowski J., Ślopek S. 1981. Immunological activity of fractions of Thymus Factor X (TFX). Arch. Immun. Ther., 29: 115-120.
• Glenner G. G. 1980. Amyloid deposits and amyloidosis. Beta-fibrilloses. New Engl. J. Med., 302: 1283-1292.
• Goch J. H., Tchórzewski H., Niedworak J., Tkaczewski W., Offierska H., Soszyńska W. 1981. Test transformacji blastycznej limfocytów i zahamowania migracji leukocytów w przebiegu przewlekłego wirusowego zapalenia mięśnia sercowego u ludzi. Immunol. Polska. 3-4: 239-248.
• Goto F., Nakamura S., Goto K., Yoshinaga M. 1984. Production of a lymphocyte proliferation potentiating factor by purified polymorphonuclear leucocytes from mice and rabbits. Immunology, 53: 683-694.
• Grzybek-Hryncewicz K. 1970a. Metody badania dopełniacza. W: Immunologia Praktyczna. Red. S. Ślopek. PZWL Warszawa.
• Grzybek-Hryncewicz K. 1970b. Pomiar aktywności fagocytarnej in vitro i in vivo. W: Immuno­logia Praktyczna. Red. S. Ślopek. PZWL Warszawa, s. 423-450.
• Grzybek-Hryncewicz K., Meleżyńska-Matej M., Kotlarek-Hans S., Kaiser A. 1981. Studies on pha­gocytosis in leukemia.II. Phagocytic and bactericidal activities of leucocytes and sepa­rated granulocytes of the peripheral blood in acute leukemia. Arch. Immun. Ther., 29: 679-689.
• Guiroy D. C., Williams E. S., Yanagihara R., Gajdusek D. C. 1991a. Topographic distribution of scrapie amyloid-immunoreactive plaques in chronic wasting disease in captive mule deer (Odocoileus hemionus hemionus). Acta neuropath., 81: 475-478.
• Guiroy D. C., Williams E. S., Yanagihara R., Gajdusek D. C. 1991b. Immunolocalization of scrapie amyloid (PrP27-30) in chronic wasting disease of Rocky Mountain elk and hybrids of captive mule deer and white-tailed deer. Neurosci. Lett., 126: 195-198.
• Hadden J. W., Hadden E. M., Haddov M. K., Goldberg N. D. 1972. Guanosine 3˒5˒cyclic mono­phosphate: a possible intercellular mediator of mitogenic influences in lymphocytes. Proc. Natl. Acad. Sci., 69: 3024-3027.
• Hermanowicz A., Marek E., Gadowska-Cicka A., Wożniakowa M., Krzyszkowska A., Żmudziński J. 1975. Izolacja komórek mononuklearnych w gradiencie fikolu i uropoliny. Pol. Arch. Med. Wew., 54: 267-271.
• Hinter H., Stossl H., Hopfl R., Grubauer G., Fritsch P. 1988. Amyloid K. Hautarzt. 39(7): 419-425.
• Hol P. R., Andel А. С. van, Ederen A. M. van, Draayer J., Gruys E. 1985. Amyloid enhancing factor in hamster. Br. J. exp. Path. 66(6): 689-697.
• Hol P. R., Snel F. W., Niewold Т. A., Gruys E. 1986. Amyloid enhancing factor AEF in the patogenesis of AA-amyloidosis in the hamster. Virchows Arch. B. (Cell Path.), Inci. Mol. Pathol. 52(3): 273-281.
• Horwitz S., Groshong Т., Albrecht H., Hong R. 1975. The active rosette test in immunodeficien­cy diseases. Clin. Immun. Immunopath., 4: 405-414.
• Inoue S. 1991. Pentosome - a new connective tissue component - is a subunit of amyloid P. Cell Tissue Res., 263: 431-438.
• Johnson A. M. 1986. Immunoprecipitation in gels. In: Manual of Clinical Laboratory Immu­nology (Third Edition). Editors: Noel R. Rose, Herman Friedman, John L.Fakey. Ame­rican Society for Microbiology. Washington D. C., s. 14-24.
• Johnson K. H., Wernstedt Ch., O'Brien T. D., Westermark P. 1991. Amyloid in the Pancreatic Islets of the Cougar (Felis Concolor) is Derived from Islet Amyloid Polypeptide (IAPP). Comp. Biochem. Physiol. 98B(1): 115-119.
• Judson D. G., Dixon J. B. 1985. Depressing of lymphocyte reactivity by granulocytes in equine whole blood culture. Vet. Immun. Immunopath., 8: 289-298.
• Kaa Ch. A. van de ., Hol P. R., Huber J., Linke R. P., Kooiker C. J., Gruys E. 1986. Diagnosis of the type of amyloid in paraffin wax embedded tissue sections using antisera against human and animal amyloid proteins. Virchows Arch. (Path. Anat), 408: 641-664.
• Kantor Т. G. 1975. Design of therapeutic trials for Dimethyl Sulfoxide. Ann. N. Y. Acad. Sci., 243(1): 390-395.
• Kedar I., Ravid M. 1980. The role of polymorphonuclear leucocytes and T lymphocytes in experimental murine amyloidosis. Eur. J. Clin. Invest., 10(1): 63-65.
• Kisilevsky R. 1987. From arthritis to Alzheimer's disease; current concepts on the pathogene­sis of amyloidosis. Can. J. Pharm. Physiol., 65: 1805-1815.
• Kolb-Bachofen V. 1991. A Review on the Biological Properties of C-Reasctive Protein. Immu- nobiol., 183: 133-145.
• Kołakowska R., Tippner M., Prokopowicz D. 1979. Metody oznaczania aktywności lizozymu. Diagn. Lab., 15: 257-261.
• Kočubej L. N., Vinogradova O. M., Belokrinickij D. V., Sovskaja T. N., Kudjavickij A. I., Rumjanceva E. G. 1987. Issledovanie fagocitoza pri eksperimental'nom i nasledstvennom amiloido- ze. Ter. Arch., 59(11): 80-84.
• Kozlovskaja L. V., Roganova O. V., Artem"eva V. В., Mirošičenko N. G., Poljaceva L. R., Muchin N. A., Komissapeva I. A. 1983. Spontannyj test vosstanovlenija nitrosinego tetrazolija i dru­gie pokazateli funkcional'nogo sostojanija lejkocitov krovi pri zabolevanijach poček. Ter. Arch., 55(6): 32-36.
• Latvalahti J. 1952. The effect of ACTH and cortisone on experimental amyloid degeneration. Acta path, microbiol. scand. Suppl., 93: 81-85.
• Linke R. P., Nathrath W. B. 1982. Immunochemical typing of amyloid from tissue biopsies. Acta Histochem., 32: 322-328.
• Linke R. P. 1984. Monoclonal antibodies against amyloid fibryl protein AA. Production, specificity, and use for immunohistochemical localisation and classification of AA-type amyloidosis. J. Histochem. Cytochem., 32: 328-332.
• Linke R. P., Hampel H., Lobeck H., Ritz E., Bommer J., Waldherr R., Eulitz M. 1989. Lysine- -specific cleavage of ß2-microglobulin in amyloid deposits associated with hemodialy­sis. Kidney International., 36: 675-681.
• Linke R. P., Восk V., Valet G., Rothe G. 1991. Inhibition of the Oxidative Burst Response of N- Formyl Peptide-Stimulated Neutrophils by Serum Amyloid-A Protein. Biochem. biophys. Res. Commun, 173(3): 1100-1105.
• Lorenz R. J. 1960. Untersuchungen uber Dosis-Wirkugs- Beziehung und die Genauigkeit bei Virustitrierungen. Arch. Ges. Virusforsch., 10: 560-564.
• Lyon A. W., Narindrasorasak S., Young I. D., Anastassiades Т., Couchman J. R., McCarthy K. J., Kisilevsky R. 1991. Co-deposition of Basement Membrane Components during the Induc­tion of Murine Splenic AA Amyloid. Lab. Invest., 64(6): 785-790.
• Lyon A. W., Anastassiades Т., Kisilevsky R. 1993. In vivo Analysis of Murine Serum Sulfate Metabolism and Splenic Glycosaminoglycan Biosynthesis During Acute Inflammation and Amyloidosis. J. Rheumatol., 20: 1109-1113.
• Madi K., De Paola D., Duarte F., Takyia Ch., Lima R. J. 1990. Spontaneus amyloidosis in mice with malignant neopalasms. Exp. Pathol., 38: 129-134.
• Magnus J. H., Kolset S. O., Husby G. 1991. High molecular weight glycosaminoglycans in AA type amyloid fibril extracts from human liver. Ann. Rheumat. Dis., 50: 562-566.
• Majolino I., Marceno R., Pecoraro G., Scime R., Vasta S., Liberti G., Rizzo A., Indovina A., Caronia F. 1993. High-Dose Therapy and Autologous Transplantation in Amyloidosis-AL. Haema- tologica., 78(1): 68-71.
• Małdyk E., Abgarowicz Т., Polowiec Z., Wagner T. 1978. Fluorescencyjna metoda wykrywania amyloidu za pomocą optycznych rozjaśniaczy celulozy. Pat. Pol., 26(1): 81-87.
• Mathur B. B. L., Ihala С. I., Purohit R. H. 1965. Amyloidosis: An Experimental Study of the Effect of a Synthetic Corticosteroid Betnasol (Betamethasone) on the Formation and Resorption of Amyloid. Lab. Invest., 14(5): 594-595.
• Matusiewicz R., Wiśniewski J., Śliwiński J. 1985. Immunoregulating Influence of Levamisole on Migration of Leukocytes in vivo and in vitro in Patientes Treated for a Long Time with Corticosteroids. Arch. Immun. Ther., 33: 763-767.
• Mayr В., Schlegar W. 1978. Untersuchungen über Erythrozytenrosetten bildende periphere T-Zellen bei Rind,Schwein und Pferd. Berl. Münch. Tierärztl. Wschr., 91: 437-439.
• Mayr В., Schlegar W. 1979. Untersuchungen über Komplementrosetten-bildende periphere Lymphozyten bei Rind, Schwein und Pferd. Wiener Tierärztl. Mschr., 86: 13-14.
• Mayr В., Radaszkiewicz Т., Schleger W. 1980. Untersuchungen über Schaferythrozytenrosetten- bildende Thymuslymphozyten bei Rind und Schwein. Dtsch. Tierärztl. Wschr., 87:5-66.
• McAdam K. P., Foss N. Т., Garcia C., DeLellis R., Chedid L., Rees R. J., Wolff S. M. 1983. Amyloidosis and the serum amyloid A protein response to muramyl dipeptide analogs and different mycobacterial species. Infect. Immun. 39(3): 1147-1154.
• Meuer S. C., Hussy R. E., Fabbi H., Fox D., Acuto O., Fitzgerald K. A., Hodgon J. C., Protentis J. P., Schlossman S. F., Reinherz е. L. 1984. An alternative pathway of T-cell activation: a functional role for the 50 Kd Til sheep erythrocyte receptor protein. Cell, 36: 897-906.
• Milanese C., Richardson N. E., Reinherz E. L. 1986. Identification of a T helper cell-derived lymphokine that actives resting T lymphocytes. Science, 231: 1118-1122.
• Mitchell T. I., Coon Ch. I., Brinckerhoff С. e. 1991. Serum Amyloid A(SAA3) Produced by Rabbit Synovial fibroblast Treated with Phorbol Esters or Interleukin 1 Induces Syn­thesis of Collagenase and Is Neutralized with Specific Antiserum. J. Clin. Invest., 87: 1177-1185.
• Miura K., Baba S., Shirasawa H., Ju S. Т., Cohen A. S., Shirahama T. 1992. Intraperitoneal amyloid formation by amyloid enhancing factor - rich macrophages in ascitic fluid. Virchows Arch. B.(Cell Path.), Inci. Mol. Pathol. 62(4): 245-250.
• Moriya N., Miyawaki K., Seki H., Kubo M., Nagaoki Т., Okuda N., Taniguhi N. 1979. Induction of suppressor activity on В cell differentiation in human T cell subsets without Fc (IgG) receptors by levamisole. Scand. J. Immun., 10: 535-541.
• Muchin N. A., Roganova О. V., Kozlovskaja L. V., Vinogradova О. M., Kočubej L. N. 1980. Fagocitarnaja funkcija nejtrofllov pri amiloidoze. Ter. Arch., 52(8): 116-118.
• Naor D. 1992. Biofunctional T Cell Clones Challenge the Traditional Compartmentalization Concept of the Immune System. Arch. Immun. Ther., 40: 67-70.
• Niewold Th. A., Gruys E., Kisilevsky R., Shirahama T. S. 1991. Fibril amyloid enhancing factor (FAEF)-accelerated amyloidosis in the hamster is not dependent on serine esterase activity and mononuclear phagocytosis. Scand. J. Immun., 34(1): 101-107.
• Niewold Th. A, Gruys E., Arakawa Т., Shirahama Т., Kisilevsky R. 1993. Recombinant Human Tumor Necrosis Factor-a (rhTNF-a) and rhTNF-a Analogue Enhance Amyloid Deposi­tion in the Syrian Hamster. Scand. J. Immun., 37: 29-32.
• Niewold Th. A., Flores Landeira J. M., Heuvel. L. P. W. J. van den, Ultee A., Tooten P. C. J., Veerkamp J. H. 1991. Characterization of proteoglycans and glycosaminoglycans in bovine renal AA-type amyloidosis. Virchows Arch. B. (Cell Path.), 60: 321-328.
• Numerof R. P., Sipe J. D., Trehu E. G., Dinarello Ch. A., Mier J. W. 1992. Suppression of IL-2- Induced SAA Gene Expression in Mice by the Administrartionn of an IL-1 Receptor Antagonist. Cytokine., 4(6): 555-560.
• Ohkawara S., Matsukawa A., Yoshinaga M. 1992. Neutrophils as the Major Producer of Interleu- kin 1 and Its Inhibitor at the Inflammatory Site in Rabbits. Arch. Immun. Ther., 40: 11-16.
• Okada M., Miyazaki S., Hirasawa Y. 1993. Increase in plasma concentration of ubiquitin in dialysis patients: possible involvement in b2-microglobulin amyloidosis. Clin. Chim. Acta. 220(2): 135-144.
• Park B. W., Fikrig S. M., Smithwick E M. 1968. Infection and nitrobluetetrazolium reduction by neutrophils. Lancet., 2: 532-534.
• Pepys M. В., Baltz M. L. 1983. Acute-phase proteins with special reference to C-reactive protein and related proteins (pentaxins) and serum amyloid A protein. Adv. Immun., 34:141-212.
• Polevščikov А. В., Nazarov P. G. 1992. Vlijanie C-reaktivnogo belka i nejtrofilov na mitoge- ninducirovannuju blasttransformaciju limfocitov eloveka. Immunologija. 6: 37-39.
• Popowski J. 1993. Priony. Post. Mikrobiol., XXXII, 1-2: 53-67.
• Potapnev M. P., Pečkovskij D. V. 1992. Vlijanie citokinov vospalenija na fagocitoz i baktericid- nuju aktivnocť nejtrofilov čeloveka. Immunologija., 6: 34-36.
• Prelli F., Pras M., Shtrasburg S., Frangione B. 1991. Characterization of High Molecular Weight Amyloid A Proteins. Scand. J. Immun., 33: 783-786.
• Prusiner S. В., Torchia M., Westaway D. 1991. Molecular Biology and Genetics of Prions- Implications for Sheep Scrapie, „Mad Cows" and the BSE Epidemic. Cornell Vet., 81(2): 85-101.
• Puchtler H., Sweat F., Levina M. 1962. On the binding of Congo red by amyloid. J. Histochem.. Cytochem., 10: 355-364.
• Quon D., Wang Y., Catalano R., Scardina J. M., Murakami K., Cordell B. 1991. Formation of ß-amyloid protein deposits in brains of transgenic mice. Nature. 352(18): 239-241.
• Rajan A., Vikram Reedy M., Sreekumaran Т., Valsala K. V., Vijayan N. 1982. Evaluation of the cell mediated immune resoponse in pigs using 2,4-dinitrochlorobenzene. Vet. Rec. 110(8): 173-174.
• Ranlɸv P. 1966. Phagocytosis in experimental mouse amyloidosis. Acta path, microbiol. scand., 68(1): 19-28.
• Raynes J. G., McAdam K. P. W. J. 1991. Serum Amyloid A Isoforms in Inflammation. Scand. J. Immun., 33: 657-666.
• Reid c., Hebert L., Pozzulo G., Gervais F. 1993. Splenic macrophage activation and functions in amyloid enhancing factor - induced secondary amyloidosis. Study of phagocytosis killing, respiratory burst, and MHC class II surface expression. J. Leukoc. Biol., 53(6): 651-657.
• Renoux G. 1985. In: The modulation of Immunity. Ed. M. S. Mitchell, Pergamon Press,Oxford, New York, Tbronto, Sydney, Frankfurt, 393.
• Rijswijk M. H. van, Hensden C. W. G. J. van. 1979. The potassium permanganate method. A reliable method for differentiating amyloid AA from other forms of amyloid in routine laboratory practice. Am. J. Path., 97: 43-58.
• Rosiecka G. 1979. Przeciwciała cytotoksyczne dla limfocytów autologicznych w surowicy chorych na reumatoidalne zapalenie stawów. Immunol. Polska., 1: 45-49.
• Rotkiewicz, Т., Koska J., Szarek J., Ruta A., Wojciechowski В., Piekut A. 1986. Wpływ splenektomii na rozwój doświadczalnej amyloidozy u świń miniaturowych. X Zjazd Naukowy PTP Białystok, s. 74-75.
• Rotkiewicz Т., Ruta A., Rotkiewicz Z. 1989. Wpływ preparatu TFX-Polfa na rozwój doświadczal­nej skrobiawicy u świń. XI Zjazd Naukowy Polskiego Towarzystwa Patologów, Poznań, s. 100-101.
• Rotkiewicz Т., Rotkiewicz Z., Вomba G., Wiśniewska M. 1992. Wpływ lewamizolu na rozwój ekspe­rymentalnej skrobiawicy typu AA u świń. XII Zjazd Naukowy Polskiego Towarzystwa Patologów, Olsztyn. Pat. Pol. , 43(3): 132.
• Rowland P. H., Valentine В. A., Stebbins K. E , Smith С. А. 1991. Cutaneous Plasmacytomas with Amyloid in Six Dogs. Vet. Path., 28: 125-130.
• Rosenthal C. J., Franklin E. C. 1975. Variation with Age and Disease of an Amyloid A Protein-Related Serum Component. J. Clin. Invest., 55: 746-753.
• Rubin L. F. 1975. Toxicity of Dimethyl Sulfoxide, alone and in combination. Ann. N. Y. Acad. Sci., 243(1): 98-103.
• Rukosuev V. S. 1973. Ob učastii g-głobułina i specifičeskich antitel v formirovanii amiloida. Arch. pat., 11: 33-38.
• Rzeszutko W. 1992. TFX-Polfa in the Treatment of Transplantable Morris 5123 Hepatoma in Buffalo Rats. Pat. Pol., 43:58-62.
• Saile R., Kandoussi A., Deveaux M., Descamps J., Hachulla E., Cachera C. 1991. Quantification of Serum Amyloid P by Enzyme-Linked Immunosorbent Assay. Clin. Chem., 37(10): 1742-1744.
• Sasaki M., Sekizawa Т., Takahashi H., Abo T., Kumaga K 1975. Heterogeneity of human T lymphocytes to bind sheep erythrocytes and mitogenic respones on their subpopulations. J. Immun., 115: 1509-1514.
• Schluederberg A. 1965. Immune globulins in viral infections. Nature, 205: 1232-1236.
• Schröder J. M. 1992. The Neutrophil-Activating Peptide 1 /Interleukin 8, a Novel Neutro­phil Chemotactic Cytokine. Arch. Immun. Ther., 40: 23-31.
• Schultz D. R., Arnold P. J. 1990. Properties of four acute phase proteins: C-reactive protein, serum amyloid A protein, alfa 1-acid glycoprotein, and fibrinogen. Semin. Arthritis Rheum., 20(3): 129-147.
• Shepard E. G., Kelly S. L., Anderson R., Fridkin M. 1992. Characterisation of neutrophil mediated degradation of human C-reactive protein and identification of the protease. Clin. Exp. Immun., 87: 509-519.
• Sillus M., Saeger W., Linke R. P., Müller D., Voigt С. 1993. Cerebral amyloid angiopathy. Frequency, significance and immunohistochemistry. Zentbl. Path., 139 (3): 207-215.
• Sil'vestrov V. P., Provotorov V. M., Nikitin A. V. 1981. Kliničeskaja effektivnosť i vlijanie levamizola na immunologičeskie pokazateli u bol'nych infeekcionnoallergičeskoj bronchial'noj astmoj. Ter.Arch., 53(l):90-94.
• Sipe J. D., Bartle L. M., Loose L. D. 1992. Modification of Proinflammatory Cytokine Pro­duction by the Antirheumatic Agents Tenidap and Naproxen. A Possible Correlate with Clinical Acute Phase Response. J.Immun., 148(2): 480-484.
• Smith J. W., Steiner A., Newberry W. M., Parker C. W. 1971. Cyclic adenosine 3˒5˒-monopho- sphate in human lymphocytes. Alterations after phytohemagglutinin stimulation. J. Clin. Invest. 50: 423-441.
• Snow A. D., Kisilevsky R., Stephans С., Anastassiades Т. 1987. Characterization of tissue and plasma glycosaminoglycans during experimental AA amyloidosis and acute inflamation. Lab. Invest., 56: 665-675.
• Soppi E., Lassila O., Viljanen M. K., Lehtonen O. P., Eskola J. 1979. In vivo effect of levamisole on cellular and humoral immunity in normal chickens. Clin. Exp. Immun., 33: 609-614.
• Stadnyk A. W., Gauldie J. 1991. The acute phase protein response during parasitic infection. In: Immunoparasitology Today. Elsevier Trends Journalis, Cambridge, p A7-A12.
• Szuperski Т., Piotrowski A., Rotkiewicz Т., Szarek J., Koska J., Rotkiewicz Z. 1980a. Experimentelle Amyloidose bei Miniaturschweinen. Z. Rheumatol., 39: 223-230.
• Szuperski Т., Piotrowski A., Rotkiewicz Т., Szarek J., Koska J. 1980b. Experimental amyloidosis in miniature pigs. International Academy of Pathology. Post Congress Meating. Buda­peszt, Summariess, s. 83.
• Szuperski Т., Piotrowski A., Rotkiewicz Т., Szarek J., Koska J., Rotkiewicz Z. 1980c. Influence of DMSO and Hydrocortisone on Experimental Amyloidosis in Miniature Pigs. International Academy of Pathology. Post Congress Meating. Budapeszt, Summariess, s.83.
• Symoens J., Rosenthal M. 1977. Levamisole in the modulation of the immune response. The current experimental and clinical state. J. Reticuloendothel. Soc., 21: 175-221.
• Ślopek S., Giełdanowski J., Kowalczyk-Bronisz S. H. 1980. Immunobiological and Pharmacologi­cal Properties of Thymus Factor X (TFX). I Biological and Pharmacological Activity. Arch. Immun. Ther., 28: 827-851.
• Tchórzewski H. 1992. Do Granulocytes Express the Immunoregulatory Functions? Arch. Im­mun. Ther., 40: 5-9.
• Teilum G. 1952. Cortison-ascorbic acid interaction and the pathogenesis of amyloidosis: mechanism of action of cortisone on mesenchymal tissue. Ann. Rheumat. Dis., 11(2): 119-136.
• Tiku K., Tiku M. L., Skosey J. L. 1986. Interleukin 1 production by human polymorphonucle­ar neutrophils. J. Immun., 136: 36-77.
• Traycoff R. В., Wortsman J., Myers W. L., Rogers W. 1984. The significance of the „active" E-rosette forming cells. Clin. Immun. Immunopath., 13: 383-393.
• Uchida K., Okuda R., Yamaguchi R., Tateyama S., Nakayama H., Goto N. 1993. Double-Labeling Immunohistochemical Studies on Canine Senile Plaques and Cerebral Amyloid Angio­pathy. J. Vet. Med. Sci., 55(4): 673-647.
• Vogel K. G., Trotter J. A. 1987. The effect of proteoglycans on the morphology of collagen fibryla formed in vitro. Collagen Rel. Res., 7: 105-114.
• Wawrzkiewicz J., Wawrzkiewicz K. 1992. Priony zakaźne replikacyjne formy białka. Medycyna Wet. 48(ll):483-486.
• Westermark G. T. 1990. Protein AA and basement membrane components in renal amyloid deposits. LinkÖping University Medical Dissertations , No 324.
• Wiktorowicz К 1989. Wpływ białka C-reaktywnego (CRP) na reaktywność limfocytów in vitro. Immunol. Polska., 2: 129-130.
• Wisniewski Th., Frangione B. 1992. Apolipoprotein E: a pathological chaperone protein in patients with cerebral and systemic amyloid. Neurosci. Lett., 135: 235-238.
• Wiśniewski H. ., Barcikowska M„ Kida E. 1991. Phagocytosis of beta I A4 amyloid fibrils of the neuritic neocortical plaques. Acta Neuropath.Berl., 81(5): 588-590.
• Wood D. C., Wood J. 1975. Pharmacologic and biochemical considerations of Dimethyl Sulfoxide. Ann. N. Y. Acad. Sci. 243(1): 7-9.
• Wybran J., Goaverts A. 1978. The resetting factor of human mixed lymphocyte cultures. Clin. Immun. Immunopath., 9: 240-247.
• Wybran J., Dupont E. 1982. The active T rosette: an early marker for T-cell activation. Ann. Immunol. (Inst. Pasteur) 133D: 211-218.
• Yamaguchi H., Nakazato Y., Shoji M., Takatama M., Hirai S. 1991. Ultrastructure of diffuse plaques in senile dementia of the Alzheimer type: comparison with primitive plaques. Acta Neuropath., 82: 13-20.
• Yokota Т., Takahashi M., Ishihara Т., Yamashita Y., Gondo Т., Kawamura S., Hoshii Y., Koga M., Iwata Т., Uchno F. 1991. Amyloid enhancing factor (AEF). Isolation and biochemical and pathological characteristics. Acta Path, jap., 41(11): 978-805.
• Young I. D., Ailles L., Narindrasorasak S., Tan R., Kisilevsky R. 1992. Localization of the Base­ment Membrane Heparan Sulfate Proteoglycan in Islet Amyloid Deposits in Type II Diabetes Mellitus. Arch. Path. Lab. Med., 116: 951-954.
• Yoshinaga M., Nishime K., Nakamura S., Goto F. 1980. A PMN derived factor that enhances DNA synthesis in PHA or antigen stimulated lymphocytes. J. Immun., 124: 94-105.
• Yu D. T. Y. 1975. The response of human „early" and „late" rosette forming lymphocytes to mixed and autologous lymphocyte cultures and mitogens. Clin. Immun. Immunopath., 10: 11-18.